Wed, May 14, 8:39 PM (29 days ago)
### Alumis Inc. (ALMS) Q1 2025 Financial Summary **Financial Health and Performance Metrics:** - **Revenue:** $17.4 million, primarily from a collaboration agreement with Kaken Pharmaceutical Co., Ltd. - **Profit Margins:** Negative, with a net loss of $99.0 million. - **Cash Flow:** Negative cash flow from operations at $80.4 million, partially offset by $39.4 million from investing activities. - **Earnings Changes:** Net loss increased by $49.1 million compared to Q1 2024. **Quarterly Performance Discussion:** - **Revenue Growth:** Significant increase in revenue due to the collaboration agreement with Kaken. - **Operating Expenses:** Increased by $71.3 million, driven by higher research and development costs. - **Cash Flow:** Negative cash flow from operations, indicating significant investment in R&D and operational expenses. **Trends and Uncertainties:** - **R&D Investment:** Continued heavy investment in R&D, particularly for ESK-001 and A-005. - **Merger with ACELYRIN:** Potential impact on future operations and financial health. - **Regulatory and Market Risks:** Uncertainties related to regulatory approvals and market acceptance. **Future Operations Impact:** - **Continued Investment:** Expectation of sustained high R&D expenses. - **Merger Integration:** Potential benefits and challenges from the merger with ACELYRIN. - **Financial Stability:** Need for additional funding to support ongoing operations and future growth.